

November 5, 2024
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice of Appointment of Executive Vice President, Corporate Officer, and Global CMO

TOKYO, November 5, 2024 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, hereinafter “Symbio”) today announced that effective November 4, 2024, Dr. Jay Marshall Feingold, MD, PhD, (hereinafter “Dr. Feingold”) will be joining Symbio as Executive Vice President, Corporate Officer, and concurrently, as Global Chief Medical Officer (“CMO”). Dr. Feingold will also serve as Senior Vice President of Symbio Pharma USA, Inc. (established in May 2016, a wholly-owned U.S. subsidiary of Symbio Pharmaceuticals Limited).

Moving forward, as our company expands its business into hematological malignancies and solid tumors in addition to post-transplant viral infections, Dr. Feingold, who has a career as a transplant physician and extensive development experience in major blood cancers and solid tumors, will lead our global operations to further strengthen our global development organizational structure. By accelerating the development and commercialization of BCV in Europe, the United States, and Japan, we will steadily grow as a global specialty pharmaceutical company.

Statement from Dr. Jay Feingold: “I am excited to work with the Symbio team to further develop BCV in multiple therapies for patients seeking new treatments for devastating diseases that currently have no treatment options. We will strive to achieve results as quickly as possible while focused on quality and patient quality of life.”

Statement from Fuminori Yoshida, President and CEO of Symbio: “I am very pleased to welcome Dr. Feingold, who has outstanding knowledge of the global development business, a proven track record of developing numerous new drugs, and is also an experienced transplant physician, to our management team. We will further strengthen our development infrastructure to achieve a global specialty pharmaceutical company.”

[Contact]

Investor Relations, Administrative Division

Tel: +81(0)3 5472 1125

1. Appointment of Executive Vice President, Corporate Officer and Global CMO of Symbio

Name	Title
Jay Marshall Feingold	Global Chief Medical Officer and Executive Vice President (Senior Vice President of SPU)

2. Date of appointment: November 4, 2024

3. Profile of the newly appointed Executive Vice President, Corporate Officer and Global CMO

2000 2007 2010 2014 2021 2023 2024	Director, Global Medical Affairs, Senior Director, Global Medical Affairs, Executive Director, Global Medical Affairs, Assistant Vice President Global Medical Affairs, Wyeth Vice President Clinical Research & Development, and Global Therapeutic Area Director, Oncology, Wyeth Vice President, US Medical Affairs, Daiichi Sankyo Senior Vice President and Chief Medical Officer, ADC Therapeutics Chief Medical Officer, Pyxis Oncology Chief Medical Officer, Tagworks Pharmaceuticals Executive Corporate Officer and Global CMO of Symbio Pharmaceuticals limited, Senior Vice President of SPU
1985 1986 1988 1992 1995	Ph.D., Molecular Biology, Albert Einstein College of Medicine M.D. degree, Albert Einstein College of Medicine, Bronx Fellow, Hematology/Oncology, Pediatrics, UCLA Center for Health Sciences Assistant Professor, Pediatrics, Medicine & Immunology/Microbiology, Rush University School of Medicine Assistant Professor of Medicine/Pediatrics, Associate Director, Pediatric Section & Alternative Donor Transplant Program, Hematology/Oncology Div.; Univ. of Connecticut Health Center/John Dempsey Hospital

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The Company’s underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.